Abstract
Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifying determinants of response, we performed molecular characterization of tissues and circulating tumor DNA (ctDNA) from 61 patients with mGC who were treated with pembrolizumab as salvage treatment in a prospective phase 2 clinical trial. In patients with microsatellite instability-high and Epstein–Barr virus-positive tumors, which are mutually exclusive, dramatic responses to pembrolizumab were observed (overall response rate (ORR) 85.7% in microsatellite instability-high mGC and ORR 100% in Epstein–Barr virus-positive mGC). For the 55 patients for whom programmed death-ligand 1 (PD-L1) combined positive score positivity was available (combined positive score cut-off value ≥1%), ORR was significantly higher in PD-L1(+) gastric cancer when compared to PD-L1(−) tumors (50.0% versus 0.0%, P value <0.001). Changes in ctDNA levels at six weeks post-treatment predicted response and progression-free survival, and decreased ctDNA was associated with improved outcomes. Our findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bass, A. J. et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
Station, W. (ed) Keytruda (Pembrolizumab) Injection, for Intravenous Use (Merck & Co., 2015).
Fuchs, C. S. et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J. Clin. Oncol. 35, 4003–4003 (2017).
Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471 (2017).
Muro, K. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 17, 717–726 (2016).
Fuchs, C. S. et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J. Clin. Oncol. 35, 4003–4003 (2017).
Derks, S. et al. Abundant PD-L1 expression in Epstein–Barr virus-infected gastric cancers. Oncotarget 7, 32925–32932 (2016).
Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956–965 (2016).
Shah, M. A. et al. Molecular classification of gastric cancer: A new paradigm. Clin. Cancer Res. 17, 2693–2701 (2011).
Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).
Razvan Cristescu, R. M. et al. Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab. J. Clin. Oncol. 35, suppl no. 7 (2017).
Cristescu, R. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449–456 (2015).
Cho, J. et al. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget 8, 13320–13328 (2017).
Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
Watanabe, T. et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 66, 9804–9808 (2006).
Cibulskis, K. et al. (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219.
Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).
Kuziora, M. & Ranade, K. Circulating tumor DNA (ctDNA) variant allele frequencies are reduced in responders to durvalumab and low baseline variant allele frequencies are associated with improved overall survival in NSCLC patients. Cancer Res. 77, abstr. 582 (2017).
Kuziora, M. et al. Early reduction in circulating tumor DNA is associated with survival of urothelial carcinoma patients treated with durvalumab. J. Clin. Oncol. abstr. 11538, 36 (2017).
Stephane Terry, P. S. et al. New insights into the role of EMT in tumor immune escape. Mol. Oncol. 11, 824–846 (2017).
Lee, J. et al. Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget 8, 66305–66315 (2017).
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
Interpretation Manual—Gastric or Gastroesophageal Junction Adenocarcinoma. Vol. 2018 (Agilent, 2018).
Song, H. J. et al. Host inflammatory response predicts survival of patients with Epstein–Barr virus-associated gastric carcinoma. Gastroenterology 139, 84–92.e82 (2010).
Lanman, R. B. et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 10, e0140712 (2015).
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
Sherry, S. T., Ward, M. & Sirotkin, K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 9, 677–679 (1999).
Forbes, S. A. et al. (2010) COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652–D657.
McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H. & Pritchard, C. C. (2014) Microsatellite instability detection by next generation sequencing. Clin. Chem. 60, 1192–1199.
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. (2016) DeconstructSigs: Delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31.
Nevins, J. R. et al. Towards integrated clinico-genomic models for personalized medicine: Combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum. Mol. Genet. 12, R153–R157 (2003).
Coppola, D. et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179, 37–45 (2011).
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Acknowledgements
This work was supported by the MISP program at Merck Sharp & Dohme Corp., USA, and a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI16C1990) (to J.L. and K.-M.K.). We thank D. Kaufman for drafting the manuscript. We thank J. Park at Samsung Medical Information and Media Servces at Samsung Medical Center for dedicated support with image work.
Author information
Authors and Affiliations
Contributions
The concept and clinical design were performed by J.L., S.T.K., R.C., K.-M.K., and W.K.K. J.L., S.T.K., R.C., A.J.B., J.I.O., K.-M.K., and W.K.K. wrote the manuscript. All clinical data analyses were done by S.T.K., R.C., K.-M.K., J.I.O., K.K., and J.L. All genomic analyses were performed by R.C., A.J.B., J.I.O., K.K., X.Q.L., X.S., A.T., P.S.K., J.C., and A.L. Clinical trial protocol development and clinical trial procedures were done by H.J., M.L., S.L., S.H.P., J.O.P., Y.S.P., H.Y.L., H.L., M.C., W.K.K., and J.L. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
R.C., X.Q.L., X.S., J.C., P.S.K., and A.L. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. J.I.O. and A.T. are employees of Guardant Health, USA.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1 and 2, and Supplementary Tables 1 and 2
Rights and permissions
About this article
Cite this article
Kim, S.T., Cristescu, R., Bass, A.J. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24, 1449–1458 (2018). https://doi.org/10.1038/s41591-018-0101-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0101-z
This article is cited by
-
Construction of a gene model related to the prognosis of patients with gastric cancer receiving immunotherapy and exploration of COX7A1 gene function
European Journal of Medical Research (2024)
-
Single-cell N6-methyladenosine-related genes function within the tumor microenvironment to affect the prognosis and treatment sensitivity in patients with gastric cancer
Cancer Cell International (2024)
-
Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors
Journal of Translational Medicine (2024)
-
Sex disparities revealed by single-cell and bulk sequencing and their impacts on the efficacy of immunotherapy in esophageal cancer
Biology of Sex Differences (2024)
-
A novel biomarker associated with EBV infection improves response prediction of immunotherapy in gastric cancer
Journal of Translational Medicine (2024)